Breaking News

Enteris, Cara Therapeutics Enter Peptelligence Pact

Cara has a non-exclusive, royalty-bearing license to the Peptelligence technology to develop, manufacture and commercialize Oral KORSUVA

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Enteris BioPharma, Inc., a biotechnology company, has entered a definitive licensing agreement with Cara Therapeutics for Enteris’ Peptelligencetechnology in the ongoing development of an oral formulation of Cara’s first-in-class KOR agonist, CR845/difelikefalin, KORSUVA. Peptelligence is Enteris’ platform for the oral delivery of peptides and BCS class II, III and IV small molecules. The oral tablet formulation of KORSUVA (Oral KORSUVA) was engineered using Peptelligence, a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters